DuChemBio buys land for Jeongeup production facility, full-scale investment of ₩34.3B
Predicted impact: Low
Land purchase for a ₩34.3B facility is small versus the company's ₩200B market value and is routine.
DuChemBio듀켐바이오
176750 · KOSDAQ · ₩176750 · 듀켐바이오
₩6,400▼ ₩760 (10.61%)End-of-day · Oct 29, 2026 · End-of-day prices.
Price · 1Y −33.05%
- Market cap
- ₩182B
- Enterprise value
- ₩169B
- P/E
- 26.7×
- P/B
- 3.5×
- Dividend yield
- 0.0%
- ROE
- 13.2%
- Net margin
- 16.4%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−49.9% from the high
₩5,100Today: ₩6,210 – ₩7,330₩12,770
Returns
- 1W−24.0%
- 1M−11.6%
- 3M+17.6%
- 6M−29.2%
- YTD−32.8%
- 1Y−33.1%
- Volume today
- 540,141
- 0.9× the 20-day average
- Traded today
- ₩3.5B
- Listed shares
- 28,488,720
- EPS (12 months)
- ₩240
- Earnings yield 3.7%
AI research · Update noteDuChemBio: Model Fair Value Estimate Cut 24.4% to ₩4,009 per ShareThe evidence points to unchanged operating results but a lower model estimate, and the shares sit further above the model's range than the model's own bull case.Read the full report →
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Why is it moving?
−10.6% on Oct 29, 2026.
DuChemBio plans to buy land for a new production facility in Jeongeup. The company's total investment in the project is about ₩34.3 billion, according to a news report.
AI summary of the news and filings linked. It can be wrong; check them.
- • Foreign investors sold a net ₩266M that day
Possible reasons, not certainties. Not financial advice.
Signals
Quiet- BuzzQuietBuzz 38 of 100 (50 is a normal day for this stock).
- SentimentPositiveNews: Expansion news with a large investment, which reads as mildly positive. Community: 0 bullish, 0 bearish posts this week.
- MomentumFlat-0.8% over the last month; the price is below its 20-day average.
- News impactLow3 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
DuChemBio stock overview
DuChemBio (듀켐바이오, KRX: 176750) is listed on KOSDAQ, in the Biotech & Pharma sector. The company develops, manufactures and sells radiopharmaceuticals for diagnosing and treating cancer and brain diseases. Its shares closed at ₩6,400 on Oct 29, 2026, down 10.61% on the day, giving it a market value of ₩182B.
Key facts
- Market cap
- ₩182B
- Sector
- Biotech & Pharma
- Latest price change
- −10.61%
- As of
- Oct 29, 2026
- Main business
- The company develops, manufactures and sells radiopharmaceuticals for diagnosing and treating cancer and brain diseases.
Quick answers about DuChemBio
- What does DuChemBio do?
- The company develops, manufactures and sells radiopharmaceuticals for diagnosing and treating cancer and brain diseases. It holds the largest number of PET-CT radiopharmaceutical products in Korea and operates 12 manufacturing sites, six of which are GMP-certified. Its main products include FDG, Alzheimer's diagnostic agents, FP-CIT for Parkinson's disease, and F-DOPA, serving the domestic market and exporting a small share of sales.
- What is the market cap of DuChemBio?
- The market capitalisation of DuChemBio was ₩182B at the close on Oct 29, 2026.
- Who are the largest shareholders of DuChemBio?
- According to the latest official filings, the largest reported holders are Geoyoung (60.96%, as of Dec 27, 2024); Kim Jong-woo (8.91%, as of Dec 24, 2024); Oh Hak-gyun (5.04%, as of Aug 31, 2026).
- When is the next earnings report from DuChemBio?
- Korean companies rarely announce results dates in advance. Based on when DuChemBio filed the same report in past years, its next 3q results is expected around Nov 13, 2026.
- Does the National Pension Service own DuChemBio?
- Yes. The National Pension Service held 0.04% of DuChemBio shares as of Dec 31, 2025.
Company profile
The company develops, manufactures and sells radiopharmaceuticals for diagnosing and treating cancer and brain diseases. It holds the largest number of PET-CT radiopharmaceutical products in Korea and operates 12 manufacturing sites, six of which are GMP-certified. Its main products include FDG, Alzheimer's diagnostic agents, FP-CIT for Parkinson's disease, and F-DOPA, serving the domestic market and exporting a small share of sales.
Written by AI from the company's latest annual report.
- Korean name
- 듀켐바이오
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 김상우
- Founded
- Nov 2002
- Listed
- Dec 2024
- Listed shares
- 28,488,720
- Fiscal year ends
- Month 12
- Website
- www.duchembio.com
Similar companies
- Samsung Biologics207940 · ₩63T₩1,366,000−0.44%
- Celltrion068270 · ₩44T₩189,300−0.26%
- Alteogen196170 · ₩15T₩220,000−1.35%
- SK biopharmaceuticals326030 · ₩6.1T₩77,800+3.46%
- Yuhan000100 · ₩5.5T₩74,700−3.36%
- HLB028300 · ₩5.3T₩39,700−2.34%
- Hanmi Pharm128940 · ₩5T₩388,500+5.14%
- SAM Chun Dang Pharm000250 · ₩4.4T₩188,600−0.74%
Recent news
Next Trade Halts Trading in Bumhan Fuel Cell and Duchem Bio from the 26th as Volume Exceeds Korea Exchange
Predicted impact: Low
Trading halt on the alternative exchange due to volume; small, company-specific but limited impact.
[Yeouido Investment Division Part 2] Samsung Electro-Mechanics vs. Samsung SDI vs. Studio Dragon vs. Duchem Biotech — What's the Strategy?
Predicted impact: Low
Stock-picking TV segment; Studio Dragon already featured in similar items recently.
Recent filings
See all- Merger Completion Report (Merger)Oct 2, 2026
- New Facility Investment, etc.Sep 4, 2026
- 5%+ holding reportAug 31, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- Amended attachment: Merger decisionJul 23, 2026
Titles in Korean until English translations are added.
Also known as: DuChemBio / 듀켐바이오 / 176750 / KRX:176750
Source: KRX statistical information